Shopping Cart 0
Cart Subtotal
USD 0

Flanders Institute for Biotechnology - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Flanders Institute for Biotechnology (VIB) is a non-profit life sciences research institute that offers pharmaceutical, agricultural, and other industrial research programs. The institute offers research services in areas of cardiovascular medicine, bioinformatics, proteomics and systems biology, inflammation and immunity, and neurosciences, among others. It also provides research services in the areas of assay development and compound screening, sequencing and genotyping, purification and analysis, nanobodies, protein production, lab informatics, gateway services, bio imaging core, and others. VIB offers PhD program and doctoral and postdoctoral courses in life sciences. The institute provides solutions for translating scientific results into agricultural, pharmaceutical, and industrial applications. VIB is headquartered in Gent, Belgium.

Flanders Institute for Biotechnology-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Flanders Institute for Biotechnology, Medical Devices Deals, 2012 to YTD 2018 10

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Confo Therapeutics Raises USD7.3 Million Financing 12

Partnerships 14

BioPontis Alliance for Rare Diseases Enters into Co-Development Agreement with VIB 14

ThromboGenics Forms Joint Venture with VIB 15

Licensing Agreements 16

Oncurious Enters into Licensing Agreement with VIB 16

AstraZeneca Enters Into Licensing Agreement with VIB and CD3 17

Equity Offering 18

Aelin Therapeutics Spin Out from K.U. Leuven, University of Leuven and Flanders Institute for Biotechnology 18

Confo Therapeutics Spin Off from VIB and Vrije Universiteit Brussel 19

Acquisition 20

Intrexon Acquires ActoGeniX 20

Flanders Institute for Biotechnology-Key Competitors 22

Flanders Institute for Biotechnology-Key Employees 23

Flanders Institute for Biotechnology-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 24

Recent Developments 25

Strategy And Business Planning 25

Jun 02, 2017: New Centre for Bioassay Development and Screening (C-BIOS) launched to support early-stage drug/agro discovery 25

Government and Public Interest 26

Oct 25, 2018: Belgian researchers discover a novel method to block immunosuppression in cancer 26

Aug 30, 2018: Novel therapeutic strategy for blood vessel related disorders, such as cancer and retinopathy 28

Aug 24, 2018: New immunotherapy inhibits tumor growth and protects against metastases 30

Apr 06, 2018: Competitive ERC Advanced Grant awarded to Bart Lambrecht to study the role of protein crystallization in asthma 32

Mar 20, 2018: Two genes cooperate to trigger leukemia development 33

Jul 27, 2017: Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer's disease 34

Jun 01, 2017: Scientists give tumor-fighting cells a boost in battling bone marrow 35

May 20, 2017: Wim Versees receives Michael J. Fox Foundation grant for investigating Parkinson's disease-associated protein 36

May 04, 2017: Crucial role for XBP1 in several aspects of DC functioning and homeostasis 37

May 03, 2017: A new unexpected key player in melanoma development identified 38

Apr 20, 2017: The Baillet Latour Grant 2017 for Medical Research awarded to professor Roosmarijn Vandenbroucke (VIB-UGent) 40

Mar 23, 2017: Competitive ERC Advanced Grant awarded to Peter Carmeliet for Tumor Endothelial Cell research 41

Mar 21, 2017: PHD2 targeting overcomes breast cancer cell death upon glucose starvation 42

Mar 14, 2017: VIB: Three accomplished VIB Scientists receive ERC Consolidator grants 43

Feb 14, 2017: Researchers identify phosphorylation process vital to cancer growth 44

Feb 13, 2017: Scientists isolate new antibodies to fight human respiratory syncytial virus 46

Feb 13, 2017: Scientists isolate new antibodies to fight human respiratory syncytial virus (RSV) 47

Feb 10, 2017: Mitochondrial lipids as potential targets in early onset Parkinson's disease 49

Product News 50

Aug 22, 2017: BioXp Genomic Workstation Makes European Debut at VIB Research Institute in Belgium 50

Aug 17, 2017: Scientists unravel role of glutamine synthetase in the spread of cancer 51

May 19, 2017: Tau prevents synaptic transmission at early stage of neurodegeneration 52

May 11, 2017: Launch of IMPRiND Consortium to investigate how aggregated proteins contribute to progression of Alzheimer's and Parkinson's Disease 53

Jan 20, 2017: Protein IL-33 found to drive allergic sensitivity in the neonatal lung 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Flanders Institute for Biotechnology, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Key Facts 2

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flanders Institute for Biotechnology, Deals By Therapy Area, 2012 to YTD 2018 9

Flanders Institute for Biotechnology, Medical Devices Deals, 2012 to YTD 2018 10

Flanders Institute for Biotechnology, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Confo Therapeutics Raises USD7.3 Million Financing 12

BioPontis Alliance for Rare Diseases Enters into Co-Development Agreement with VIB 14

ThromboGenics Forms Joint Venture with VIB 15

Oncurious Enters into Licensing Agreement with VIB 16

AstraZeneca Enters Into Licensing Agreement with VIB and CD3 17

Aelin Therapeutics Spin Out from K.U. Leuven, University of Leuven and Flanders Institute for Biotechnology 18

Confo Therapeutics Spin Off from VIB and Vrije Universiteit Brussel 19

Intrexon Acquires ActoGeniX 20

Flanders Institute for Biotechnology, Key Competitors 22

Flanders Institute for Biotechnology, Key Employees 23

Flanders Institute for Biotechnology, Joint Venture 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Flanders Institute for Biotechnology, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.